Jason Bednar
Stock Analyst at Piper Sandler
(2.02)
# 3,033
Out of 4,984 analysts
183
Total ratings
35.97%
Success rate
-5.99%
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ICUI ICU Medical | Maintains: Overweight | $145 → $153 | $132.46 | +15.51% | 2 | Sep 10, 2025 | |
| COO The Cooper Companies | Maintains: Overweight | $105 → $83 | $66.71 | +24.42% | 14 | Aug 28, 2025 | |
| SOLV Solventum | Maintains: Overweight | $87 → $94 | $74.20 | +26.68% | 7 | Aug 8, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Neutral | $185 → $200 | $188.60 | +6.04% | 10 | Aug 8, 2025 | |
| MASI Masimo | Maintains: Overweight | $200 → $210 | $140.91 | +49.03% | 16 | Aug 6, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $17 → $19 | $20.88 | -9.00% | 13 | Aug 1, 2025 | |
| MMSI Merit Medical Systems | Maintains: Overweight | $110 → $105 | $83.65 | +25.52% | 13 | Jul 31, 2025 | |
| ALGN Align Technology | Maintains: Overweight | $250 → $190 | $131.86 | +44.09% | 31 | Jul 31, 2025 | |
| LUNG Pulmonx | Downgrades: Neutral | $9 → $2.5 | $1.59 | +57.23% | 12 | Jul 31, 2025 | |
| NVCR NovoCure | Reiterates: Overweight | $34 | $13.00 | +161.54% | 11 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4.5 → $3.5 | $4.06 | -13.79% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $16 | $13.36 | +19.76% | 8 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $77 | $68.64 | +12.18% | 7 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $16.05 | -19.00% | 2 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $2.40 | +87.50% | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $265 | $250.65 | +5.73% | 9 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $6 | $3.80 | +57.89% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $3.81 | +83.73% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $20 | $2.30 | +768.66% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $433.14 | -14.12% | 4 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $95 | $74.59 | +27.36% | 1 | Apr 19, 2023 |
ICU Medical
Sep 10, 2025
Maintains: Overweight
Price Target: $145 → $153
Current: $132.46
Upside: +15.51%
The Cooper Companies
Aug 28, 2025
Maintains: Overweight
Price Target: $105 → $83
Current: $66.71
Upside: +24.42%
Solventum
Aug 8, 2025
Maintains: Overweight
Price Target: $87 → $94
Current: $74.20
Upside: +26.68%
Becton, Dickinson and Company
Aug 8, 2025
Maintains: Neutral
Price Target: $185 → $200
Current: $188.60
Upside: +6.04%
Masimo
Aug 6, 2025
Maintains: Overweight
Price Target: $200 → $210
Current: $140.91
Upside: +49.03%
Envista Holdings
Aug 1, 2025
Maintains: Neutral
Price Target: $17 → $19
Current: $20.88
Upside: -9.00%
Merit Medical Systems
Jul 31, 2025
Maintains: Overweight
Price Target: $110 → $105
Current: $83.65
Upside: +25.52%
Align Technology
Jul 31, 2025
Maintains: Overweight
Price Target: $250 → $190
Current: $131.86
Upside: +44.09%
Pulmonx
Jul 31, 2025
Downgrades: Neutral
Price Target: $9 → $2.5
Current: $1.59
Upside: +57.23%
NovoCure
Jun 27, 2025
Reiterates: Overweight
Price Target: $34
Current: $13.00
Upside: +161.54%
May 8, 2025
Maintains: Neutral
Price Target: $4.5 → $3.5
Current: $4.06
Upside: -13.79%
Apr 30, 2025
Maintains: Neutral
Price Target: $20 → $16
Current: $13.36
Upside: +19.76%
Apr 30, 2025
Maintains: Overweight
Price Target: $83 → $77
Current: $68.64
Upside: +12.18%
Apr 23, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $16.05
Upside: -19.00%
Mar 28, 2025
Maintains: Overweight
Price Target: $5 → $4.5
Current: $2.40
Upside: +87.50%
Feb 3, 2025
Maintains: Overweight
Price Target: $260 → $265
Current: $250.65
Upside: +5.73%
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $3.80
Upside: +57.89%
Aug 15, 2024
Reiterates: Overweight
Price Target: $7
Current: $3.81
Upside: +83.73%
Aug 7, 2024
Maintains: Overweight
Price Target: $70 → $20
Current: $2.30
Upside: +768.66%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $433.14
Upside: -14.12%
Apr 19, 2023
Initiates: Overweight
Price Target: $95
Current: $74.59
Upside: +27.36%